prostate-cancer

Bayer AG said positive results for an experimental prostate-cancer drug could speed the drug's path to approval in an increasingly crowded market.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

Wall Street expects the world-wide market for prostate-cancer therapies, now estimated to approach $1 billion, to grow to $5 billion by 2015 as a result of the influx of new treatments, according to Morningstar Inc. Those already available are Dendreon Corp.'s Provenge, Jevtana from Sanofi SA and Johnson & Johnson's Zytiga.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

While some competition for the market is likely, prostate-cancer experts said each of the agents works differently against the disease, suggesting that they may be used either sequentially or in combination to mount the most effective assault on the disease.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

Dendreon Corp. reported higher-than-expected fourth-quarter revenue from its Provenge prostate-cancer drug, a rare bit of good news for the innovative but expensive treatment whose growth has slowed in recent months over reimbursement issues.

Dendreon Reports GainsFor Costly Cancer Drug Mia Lamar 2012

Drug maker Dendreon Corp. said Thursday it would lay off 500 employees—about one-fourth of its work force—to cut costs in response to lower-than-expected sales of its new prostate-cancer treatment Provenge.

Dendreon to Lay Off 500 Workers Peter Loftus 2011

Wall Street expects the world-wide market for prostate-cancer therapies, now estimated to approach $1 billion, to grow to $5 billion by 2015 as a result of the influx of new treatments, according to Morningstar Inc. Those already available are Dendreon Corp.'s Provenge, Jevtana from Sanofi SA and Johnson & Johnson's Zytiga.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

AstraZeneca PLC's oncology development program suffered a fresh setback Monday with news its experimental prostate-cancer pill Zibotentan failed in a late clinical trial to significantly improve overall survival.

Astra's Prostate-Cancer Drug Fails Trial Sten Stovall 2010

GlaxoSmithKline had been seeking FDA approval to market Avodart as a prostate-cancer prevention treatment on the basis of a clinical study that involved 8,000 men, which showed the product cut the risk of prostate cancer among those treated with the drug for four years, compared to those taking a placebo.

FDA Cites Cancer Risk of Some Prostate Drugs Jennifer Corbett Dooren 2011

Bayer AG said positive results for an experimental prostate-cancer drug could speed the drug's path to approval in an increasingly crowded market.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

Mr. Aschoff pointed to an increasingly competitive prostate-cancer drug market that includes Johnson & Johnson 's Zytiga, which is given as a pill and costs $5,000 a month with a median usage of eight months, as well as an experimental drug being developed by Medivation Inc. and Astellas Pharma Inc.

Dendreon Reports GainsFor Costly Cancer Drug Mia Lamar 2012